QDOT MICRO System
Biosense Webster, Inc. · Decision date Sep 10, 2026
What did the FDA decide?
The FDA record P210027/S018, with a decision of OK30 dated 2026-09-10, is a 30-Day Notice supplement to PMA P210027. The stated purpose is "to implement a repackaging and relabeling operation," and the listed supplement reason is a process change involving manufacturer, sterilizer, packager or supplier. The product code is OAE, describing a percutaneous cardiac ablation catheter for treatment of atrial fibrillation, and the applicant is Biosense Webster, Inc.
Beyond that purpose statement, the source does not specify which packaging or labeling elements change, where the operation occurs, or what validation supports it. This notice does not approve the QDOT MICRO System as a whole; it concerns a change to an existing approval identified by P210027, and the OK30 decision is a regulatory action rather than independent evidence of safety or clinical effectiveness. Any effect on the device's performance is not established by these fields.
The specialty field lists Cardiovascular, and the supplement type limits the scope to the reported process change. The supplied text does not detail the repackaging method, materials, or labeling content, so those specifics remain unknown here.
FDA approval order statement
to implement a repackaging and relabeling operation
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210027/S018
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- Decision code
- OK30
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210027 · Original PMA
QDOT MICRO System
P210027/S018 received
Application receipt date recorded by FDA.
P210027/S018 · FDA decision
30-Day Notice
P210027/S019 · Related supplement
QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER
Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA | |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P210027/S018
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

